This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical



Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact




Phase III Study Primary Endpoints

Success in ISGA: Clear or almost clearStudy Design

Phase III Study Secondary Endpoints

ISGA clear or almost clearTime to ISGA success
Phase III Study: Other EndpointsPruritusQuality of life assessmentsInfant Study: Exploratory EndpointsISGA clear or almost clear%BSA, EASI & POEM
Safety DataSafety DataPhase III Study Adverse Reactions*Pivotal trial & 48-week extension study Adverse ReactionsOpen-Label Safety Extension Study*Open-Label Safety Extension Study Rescue Therapy EndpointStudy designInfant Safety Study**Adverse ReactionsStudy design and DemographicsReal PatientsReal patient case reportsReal patient case studiesNana's experience with EucrisaBraxton's testimonialHand and fingerFace and neckOtherHand and finger5-yr-old Caucasian female - hands8-yr-old Caucasian female - hands15-yr-old Caucasian male - hand55-yr-old Caucasian female - hand64-yr-old Caucasian female - thumb70-yr-old Caucasian male - thumbFace and neck15-yr-old Caucasian male - chin18-yr-old Hispanic female - face and neck75-yr-old Caucasian male - faceOther39-yr-old Asian male - arm44-yr-old African American female - legs72-yr-old Caucasian female - legDosingSavings & SupportSavings & SupportEventsMaterialsVideosCopay CardsCost and Coverage
Prescribing InformationPatient Information Indication Patient Site
Order Copay Savings Cards
Select the number of Savings Cards required: Each offer has a unique identification number, so please make sure to distribute one to each patient.
Eligibility required. Individual savings limited to $970 per tube or $3,880 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and Conditions apply.
Please confirm the following eligibility requirements:
  • I confirm that I am not licensed to practice medicine in the state of Vermont.
  • I confirm that I am not an Advance Practice Registered Nurse ("APRN") engaged in an independent practice in the state of Connecticut.
Offer must be accompanied by a valid prescription. Each offer must be printed directly from this website. Do not photocopy.
*Indicates a required field
Select how to receive your Savings Cards:
  • Submit


    Eligibility Criteria:
    You may be eligible for the EUCRISA Copay Savings Program if you currently use private or commercial health insurance to cover a portion of your medication costs for EUCRISA.

    By using the Pfizer Dermatology Patient Access™ Copay Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

    • You are not eligible to use this card if you are enrolled in a state or federally funded prescription insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
    • You must have commercial insurance. Offer is not valid for cash-paying patients.
    • By using this copay card at participating pharmacies, eligible patients with commercial prescription drug insurance coverage for EUCRISA® (crisaborole) may pay as little as $10 per tube. Eligible patients with commercial prescription drug insurance coverage that does not cover EUCRISA may pay as little as $100 per tube. Individual savings are limited to $970 per tube. Individual patient savings are limited to $3,880 in maximum total savings per calendar year.
    • This copay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your commercial insurance plan or any other health or pharmacy benefit program.
    • You must deduct the value of this copay card from any reimbursement request submitted to your commercial insurance plan, either directly by you or on your behalf.
    • You are responsible for reporting use of the copay card to any commercial insurer, health plan, or other third party that pays for or reimburses any part of the prescription filled using the copay card, as may be required. You should not use the copay card if your insurer or health plan prohibits use of manufacturer copay cards.
    • This copay card is not valid where prohibited by law.
    • Copay card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
    • Copay card will be accepted only at participating pharmacies.
    • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
    • This copay card is not health insurance.
    • Offer good only in the U.S. and Puerto Rico.
    • Copay card is limited to 1 per person during this offering period and is not transferable.
    • A copay card may not be redeemed more than once per 30 days per patient.
    • No other purchase is necessary.
    • Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you.
    • Pfizer reserves the right to rescind, revoke, or amend this offer at any time without notice.
    • Offer expires 12/31/2023.
    Thank you!

    Your savings card(s) have been emailed to: {{emailTo}}

    Thank you!

    Your Copay card download should begin now. Each offer has a unique identification number, so please make sure to distribute one to each patient.

    If your download does not start, please click here to download again.

    For questions or additional support, call 1-877-548-1739, write to Pfizer Inc., at PO Box 29387, Mission, KS 66201, or visit the EUCRISA website at

    Savings & Support Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources Loading
    Cost and Coverage

    Favorable access on many plans nationwide and is available at the lowest branded copay for many commercial and Medicare patients.

    View eligibility Loading

    To report an adverse event, please call 1-800-438-1985

    Pfizer for Professionals 1-800-505-4426

    This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

    © 2023 Pfizer Inc. All rights reserved.

    You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 


    EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

    Important Safety Information


    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    Indication EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.